{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T19:36:18Z","timestamp":1781033778838,"version":"3.54.1"},"reference-count":47,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To study the role of Osteoclast inhibitors in advanced prostate cancer metastasis treatment and their efficacy in reducing skeletal related events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods: Data Source<\/jats:title>\n                    <jats:p>A comprehensive search was done using search terms as \u201costeoclast inhibitors\u201d \u201cBisphosphonates\u201d \u201cZoledronic acid\u201d \u201c pamidronate\u201d \u201c Alendronate\u201d \u201cDenosumab\u201d \u201c Prostate cancer metastasis\u201d in pubmed and Google scholar. Relevant articles were screened and collected . The collected articles were used to frame the review and data showing use of Osteoclast inhibitors In prostate cancer bone metastasis was collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data summary<\/jats:title>\n                    <jats:p>Prostate cancer metastasizes most commonly to the skeleton thus leading to significant morbidity ranging from pain, pathological fractures to spinal cord compression and are the primary cause of patient disability and reduced quality of life.Initially, radiation therapy and radiopharmaceuticals were the mainstay of treatment however the role of Bisphosphonates and denosumab has become an integral part of therapy to manage metastatic prostate cancer. These agents significantly decrease skeletal related events and enhance patients quality of life. Emerging therapies like Radium-223 have also shown promise in reducing skeletal related events and also improving survival rates in patients with bone metastasis. Other treatment options which are being used are systemic agents like Docetaxel, cabazitaxel, hormonal therapies like abiraterone and enzalutamide. Immunotherapy with sipuleucel-T has demonstrated a reduction in mortality among prostate cancer patients with metastasis, highlighting the need for further research in this area. Ongoing studies are investigating novel agents that target both tumor cells and the bone microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Osteoclast inhibitors are effective in reducing skeletal related events in advanced bone metastasis and improve the quality of life of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241275943","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T09:34:27Z","timestamp":1724319267000},"page":"119-127","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5112-8433","authenticated-orcid":false,"given":"Shariq Ahmad","family":"Wani","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Government medical college, Srinagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1008-8275","authenticated-orcid":false,"given":"Salma","family":"Qudrat","sequence":"additional","affiliation":[{"name":"internal Medicine, Khyber teaching hospital, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Zubair","sequence":"additional","affiliation":[{"name":"Internal Medicine, Rawalpindi medical university, Rawalpindi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Internal Medicine, Virginia commonwealth university, Richmond, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babar","family":"Gulzar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Government medical college, Srinagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundal","family":"Aziz","sequence":"additional","affiliation":[{"name":"Internal Medicine, Khyber medical university, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsalan","family":"Inayat","sequence":"additional","affiliation":[{"name":"Internal Medicine, HSHS St Mary's Hospital, Decatur, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danish","family":"Safi","sequence":"additional","affiliation":[{"name":"Internal Medicine, WVU hospital, Morgantown, WV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Kamran","sequence":"additional","affiliation":[{"name":"Internal Medicine, Charleston Area Medical center, Charleston, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"bibr1-10781552241275943","doi-asserted-by":"crossref","unstructured":"Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: a systematic review and meta-analysis. PLoS ONE 2018; 13: e0191455.","DOI":"10.1371\/journal.pone.0191455"},{"issue":"1","key":"bibr2-10781552241275943","volume":"13","author":"J.-J.","year":"2015","journal-title":"Nat Rev Urol"},{"key":"bibr3-10781552241275943","doi-asserted-by":"crossref","unstructured":"The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer. Adv Urol 2018, Article ID 1525832, 9 pages, https:\/\/doi.org\/10.1155\/2018\/1525832.","DOI":"10.1155\/2018\/1525832"},{"key":"bibr4-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191455"},{"key":"bibr5-10781552241275943","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S40151"},{"key":"bibr6-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.08.048"},{"key":"bibr7-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.05.015"},{"key":"bibr8-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-013-0183-7"},{"key":"bibr9-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q"},{"key":"bibr10-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.02.002"},{"key":"bibr11-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0843"},{"key":"bibr12-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00425"},{"key":"bibr13-10781552241275943","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102587"},{"key":"bibr14-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24896"},{"key":"bibr15-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1016\/j.eursup.2004.09.001"},{"key":"bibr16-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2008.01.011"},{"key":"bibr17-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602767"},{"key":"bibr18-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605546"},{"key":"bibr19-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2000.0210"},{"key":"bibr20-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212299"},{"key":"bibr21-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809003"},{"key":"bibr22-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1525832"},{"key":"bibr23-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.039"},{"key":"bibr24-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.67"},{"key":"bibr25-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(03)00071-9"},{"key":"bibr26-10781552241275943","unstructured":"La Manna F, Karkampouna S, Zoni E, et al. Metastases in Prostate Cancer."},{"key":"bibr27-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2015.90"},{"key":"bibr28-10781552241275943","author":"Florimonte L","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bibr29-10781552241275943","doi-asserted-by":"publisher","DOI":"10.2174\/1566524011313040012"},{"key":"bibr30-10781552241275943","unstructured":"Smith MR, Saad F, Coleman R, et al. url onco. sept 2012 commentary on denosumab and bone metastasis free survival in men with castration resistant prostate cancer."},{"key":"bibr31-10781552241275943","unstructured":"Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastasis in men with castration resistant prostate cancer a randomized double blind study."},{"key":"bibr32-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1593\/neo.10610"},{"key":"bibr33-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4164"},{"key":"bibr34-10781552241275943","doi-asserted-by":"crossref","unstructured":"Hussain M, Corcoran C, Sibilla Cet al. Tumor genomic testing for >4000 men with metastatic castration resistant prostate cancer in phase 3 trial PRO found (olaparib).\n                      Clin Cancer Res\n                      2022; 28: 1518\u20131530.","DOI":"10.1158\/1078-0432.CCR-21-3940"},{"key":"bibr35-10781552241275943","unstructured":"Kantoff PW, Higano CS, Shore ND, et al."},{"key":"bibr36-10781552241275943","author":"Cheetham PJ","year":"2012","journal-title":"Oncol (Williston Park)"},{"key":"bibr37-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2955"},{"key":"bibr38-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.9811"},{"key":"bibr39-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5393"},{"key":"bibr40-10781552241275943","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2010.n.059"},{"key":"bibr41-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1038\/aja.2008.29"},{"key":"bibr42-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-1058"},{"key":"bibr43-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1749"},{"key":"bibr44-10781552241275943","volume":"13","author":"Hayes AR","journal-title":"Nick Pavlakis PLoS ONE"},{"key":"bibr45-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104157"},{"key":"bibr46-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1038\/nm0995-944"},{"key":"bibr47-10781552241275943","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3506"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241275943","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241275943","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241275943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:30:12Z","timestamp":1777689012000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241275943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/10781552241275943"],"URL":"https:\/\/doi.org\/10.1177\/10781552241275943","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}